Posted in | News | Business

Oxford Instruments Enters into Joint Venture with GD Intressenter AB, Comprising Omicron Nanotechnology and Scienta Scientific

Oxford Instruments plc, a leading provider of high technology tools and systems for industry and research, today announces that it has entered into a Joint Venture with GD Intressenter AB of Sweden (“GDI”) to create the world’s largest player in the highly specialised Ultra High Vacuum Surface Science field.

The JV will comprise Oxford Instruments’ Omicron Nanotechnology GmbH and associated subsidiaries (“Omicron”) and GDI’s Scienta Scientific AB and associated subsidiaries (“Scienta”).

In consideration for new shares in Scienta, Oxford Instruments has transferred all of its shares in the capital of Omicron to Scienta.  Oxford Instruments holds a 47 per cent interest in the share capital of Scienta and GDI holds 53 per cent.

The JV provides excellent opportunities to enhance product development, cut production costs and broaden the product range, while extending market reach and strengthening customer relationships.  

The Board of Directors of the JV will include representatives from GDI and Oxford Instruments.  The CEO of the new business will be Mr Johan Åman who is based in Uppsala, Sweden.  Mr Åman has been CEO of Scienta since 2013 and prior to this he held senior commercial and research positions in Mycronic AB. GDI is backed by a leading Nordic Venture Capital Firm, InnovationsKapital, and other financial investors.

In the twelve months to 31st March 2014, Omicron generated revenue of £28.5 million and a loss before tax of £0.6 million.  The gross assets of Omicron at 30th September 2014 were £26.1 million.  In the financial year to 31st December 2014, Scienta generated revenue of SEK279 million (approximately £24.6 million) and a profit before tax of SEK25 million (approximately £2.2 million).  The gross assets of Scienta at 31st December 2014 were SEK146 million (approximately £12.9 million).  Oxford Instruments has provided a term loan of SEK40 million (approximately £3.1 million) to the JV.  The transaction will result in no profit or loss on the carrying value of Omicron for Oxford Instruments.

Commenting on the establishment of the JV, Jonathan Flint, Chief Executive of Oxford Instruments, stated:

“This new venture will create the largest player in the exciting field of Surface Science and UHV engineering.   Customers will benefit from an enhanced product portfolio and improved service, and the synergies generated by merging the two businesses will provide significant efficiencies and cost savings.”

Lars Hagdahl, Chairman of GDI and of the JV, said:

“I am very pleased with the creation of this JV.  Going forward together we are a larger and stronger business that will be good for our customers, partners and employees.”

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Oxford Instruments. (2019, March 18). Oxford Instruments Enters into Joint Venture with GD Intressenter AB, Comprising Omicron Nanotechnology and Scienta Scientific. AZoM. Retrieved on May 10, 2024 from https://www.azom.com/news.aspx?newsID=43880.

  • MLA

    Oxford Instruments. "Oxford Instruments Enters into Joint Venture with GD Intressenter AB, Comprising Omicron Nanotechnology and Scienta Scientific". AZoM. 10 May 2024. <https://www.azom.com/news.aspx?newsID=43880>.

  • Chicago

    Oxford Instruments. "Oxford Instruments Enters into Joint Venture with GD Intressenter AB, Comprising Omicron Nanotechnology and Scienta Scientific". AZoM. https://www.azom.com/news.aspx?newsID=43880. (accessed May 10, 2024).

  • Harvard

    Oxford Instruments. 2019. Oxford Instruments Enters into Joint Venture with GD Intressenter AB, Comprising Omicron Nanotechnology and Scienta Scientific. AZoM, viewed 10 May 2024, https://www.azom.com/news.aspx?newsID=43880.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.